Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05654194 | Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML | completed | Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05024994 | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04965649 | Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.(TIPHI) | completed | — | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04188405 | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04848974 | Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02286726 | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT01371981 | Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 1,645 | National Cancer Institute (NCI)NIH | 5 | Jun 2, 2026 | clinicaltrials |
| NCT00085124 | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 500 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02220985 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | completed | Phase 2 | 84 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02583893 | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | completed | Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT02688140 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia(TUD-APOLLO-064) | completed | Phase 3 | 133 | Technische Universität DresdenOTHER | 5 | May 29, 2026 | clinicaltrials |
| NCT03932643 | ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant | completed | Phase 1 | 20 | University of NebraskaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT00932412 | The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)(CLARA) | completed | Phase 2 | 735 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03434730 | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04915612 | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia | completed | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05534620 | Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | completed | Phase 1 | 20 | medac GmbHINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT02949427 | The Oronasal Microbiota in Pediatric Oncology Patients | completed | — | 62 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04902833 | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms | completed | — | 18 | Massachusetts General HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04742101 | Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 57 | Institut de Recherches Internationales ServierOTHER | 6 | May 18, 2026 | clinicaltrials |
| NCT03600155 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05335369 | A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists(UR-GOAL 2) | completed | N/A | 161 | University of RochesterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05155709 | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 7 | May 7, 2026 | clinicaltrials |
| NCT05441514 | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04167917 | NTX-301 in MDS/AML | completed | Phase 1 | 22 | University of Alabama at BirminghamOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT03068819 | Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 62 | Washington University School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03580655 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | completed | Phase 2 | 107 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 24, 2026 | clinicaltrials |
| NCT03009240 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03578367 | Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. | completed | Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 21, 2026 | clinicaltrials |
| NCT04625413 | A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists(UR-GOAL 1) | completed | N/A | 15 | University of RochesterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04641910 | Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia(FLAMVAL) | completed | — | 201 | Nantes University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03466294 | Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | completed | Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04102020 | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy(VIALE-M) | completed | Phase 3 | 112 | AbbVieINDUSTRY | 19 | Apr 8, 2026 | clinicaltrials |
| NCT05972577 | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | completed | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02204085 | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 33 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 / Phase 2 | 12 | CRISPR TherapeuticsINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04745676 | A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome(SICG) | completed | N/A | 36 | University of RochesterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04107727 | Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | completed | Phase 2 | 273 | PETHEMA FoundationOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04948333 | Asciminib Treatment Optimization in ≥ 3rd Line CML-CP | completed | Phase 3 | 199 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT02467270 | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses(OPTIC) | completed | Phase 2 | 283 | TakedaINDUSTRY | 21 | Mar 17, 2026 | clinicaltrials |
| NCT03232268 | HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies(MICROSTEM) | completed | Phase 1 | 25 | Institut Paoli-CalmettesOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03226418 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | completed | Phase 2 | 75 | University of NebraskaOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT01758042 | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders(BMT) | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02975869 | A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia | completed | N/A | 160 | Massachusetts General HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02730299 | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | completed | Phase 3 | 125 | Gamida Cell ltdINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT04620681 | CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML | completed | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2026source: clinicaltrials